Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT.
- Published In:
- Journal of nuclear medicine technology, 52(3), 272-273 (2024)
- Authors:
- Baberwal, Parth, Parghane, Rahul, Basu, Sandip(2)
- Database ID:
- RPEP-07797
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07797APA
Baberwal, Parth; Parghane, Rahul; Basu, Sandip. (2024). Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT.. Journal of nuclear medicine technology, 52(3), 272-273. https://doi.org/10.2967/jnmt.123.267286
MLA
Baberwal, Parth, et al. "Identification of Wandering Masses and Tumor Heterogeneity on 68Ga-DOTATATE and 18F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT.." Journal of nuclear medicine technology, 2024. https://doi.org/10.2967/jnmt.123.267286
RethinkPeptides
RethinkPeptides Research Database. "Identification of Wandering Masses and Tumor Heterogeneity o..." RPEP-07797. Retrieved from https://rethinkpeptides.com/research/baberwal-2024-identification-of-wandering-masses
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.